Clinical trials: Dysmenorrhea
Endometriosis
A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain
A randomized study evaluating the safety and efficacy of elagolix in the management of moderate to severe endometriosis-associated pain in adult premenopausal female subjects.
- Trial name
- ELARIS EM-II (NCT01931670)
- Testing
- Elagolix
- Volunteers
- 815 people
- Sponsor
- AbbVie
Endometriosis Pelvic, Endometriosis Ovaries
PRECISION-E2: Teverelix in Women With Endometriosis - Pharmacodynamics, Safety and Precision Medicine Correlates
PRECISION-E2 is a Phase IIa randomized, placebo-controlled study evaluating the pharmacodynamic profile, safety and tolerability of teverelix in premenopausal women with moderate-to-severe pain associated with endometriosis in…
- Conditions
- Endometriosis Pelvic, Endometriosis Ovaries, Premenopausal, Endometriosis (Diagnosis)
- Trial name
- NCT07914062
- Testing
- Teverelix DP
- Volunteers
- 84 people
- Sponsor
- Antev Ltd.
Dysmenorrhea
Efficacy and Safety Study of Lidocaine Vaginal Gel for Recurrent Dysmenorrhea (Painful Periods)
The purpose of this study is to determine whether lidocaine vaginal gel is safe and effective for preventing or reducing the severity of dysmenorrhea (painful menstrual periods) compared to placebo (inactive gel).
- Trial name
- Lidocaine 04 (NCT00651313)
- Testing
- Lidocaine
- Where
- 4 sites in United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Juniper Pharmaceuticals, Inc.
Dysmenorrhea
Dose-Finding Study of PDC31 in Patients With Primary Dysmenorrhea
The purpose of this study is to determine a safe and effective dose range for intravenous administration (infusion) of PDC31 by determining the maximum tolerated dose of PDC31 in patients with primary dysmenorrhea.
- Trial name
- NCT01250587
- Testing
- PDC31
- Where
- 4 sites in Austria, Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- PDC Biotech GmbH
Healthy Volunteers
A Pilot Open-Label Crossover Bioavailability Study of Celecoxib in Healthy Volunteers
A pharmacokinetic study in healthy volunteers to determine the relative bioavailability of three formulations of celecoxib to the approved formulation.
- Trial name
- NCT00813241
- Testing
- celecoxib reference formulation, celecoxib test formulation A1, celecoxib test formulation B2
- Where
- Singapore
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pain Disorders
Crossover, Single Dose Randomized, Bioequivalence of Ketoprofen Lysine Salt Immediate Release vs Oral Solution
Objectives: The objective of the study was to investigate the bioequivalence between two formulations containing ketoprofen lysine salt (KLS) when administered as single oral doses in two consecutive study periods to healthy male…
- Trial name
- NCT02350296
- Testing
- KSL 40 mg, OKi® 80 mg
- Where
- Switzerland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Dompé Farmaceutici S.p.A
Dysmenorrhea
A Double Blind, Double Dummy, Randomized, Comparative Study Of The Efficacy And Safety Of Valdecoxib 40 Mg Twice Daily, As Needed In The First Menstrual Cycle Day And Then Once A Day, And Piroxicam 40 Mg Once A Day In The Treatment Of Patients With Primary Dysmenorrhea
To compare the analgesic efficacy, safety, and tolerability of valdecoxib versus piroxicam in subjects with moderate to severe menstrual cramping pain associated with primary dysmenorrhea.
- Trial name
- NCT00649415
- Testing
- piroxicam, valdecoxib
- Where
- 10 sites in Brazil
- Volunteers
- 154 people
- Sponsor
- Pfizer
Endometriosis
SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain
The purpose of this study is to evaluate the long-term efficacy and safety of relugolix 40 milligram (mg) once daily co-administered with low-dose estradiol (E2) and norethindrone acetate (NETA) for up to 104 weeks on…
- Trial name
- NCT03654274
- Testing
- Relugolix, Estradiol/norethindrone acetate
- Where
- 169 sites in United States, Argentina and 18 more
- Volunteers
- 802 people
- Sponsor
- Myovant Sciences GmbH
PMS, Menstrual Discomfort
Study to Evaluate Your Super's Moon Balance and Its Impact on Premenstrual Syndrome
This is an open-label observational single-group clinical trial to study the efficacy of a commercially available dietary supplement and its effect on common PMS and menstrual symptoms, as well as health-related biomarkers.
- Conditions
- PMS, Menstrual Discomfort, Menstrual Pain
- Trial name
- NCT05237661
- Testing
- Moon Balance
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Your Super, INC.
Dysmenorrhea, Dyspareunia
Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women
The purpose of the study is to evaluate the efficacy and safety of two doses of ERB-041 (75 mg and 150 mg) relative to placebo on the relief of endometriosis-related symptoms (dysmenorrhea, pelvic pain, and deep dyspareunia) in…
- Conditions
- Dysmenorrhea, Dyspareunia, Endometriosis, Pelvic Pain
- Trial name
- NCT00318500
- Testing
- ERB-041
- Where
- 70 sites in United States, Australia and 5 more
- Volunteers
- 150 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Endometriosis Related Pain
SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain
The purpose of this study is to determine the benefit and safety of relugolix 40 milligrams (mg) once daily, co-administered with low-dose estradiol (E2) and norethindrone acetate (NETA) compared with placebo for 24 weeks, on…
- Trial name
- NCT03204318
- Testing
- Relugolix, Estradiol/norethindrone acetate
- Where
- 123 sites in United States, Argentina and 11 more
- Volunteers
- 638 people
- Sponsor
- Myovant Sciences GmbH
Endometriosis
A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Women With Endometriosis.
The objective of this study is to determine the safety and efficacy of 3 asoprisnil doses (0.5 mg, 1.5 mg, and 5.0 mg) for 12 weeks in women with endometriosis.
- Trial name
- NCT00160433
- Testing
- Asoprisnil
- Volunteers
- 131 people
- Sponsor
- Abbott
Endometriosis and Dysmenorrhea
Drug Use Investigation (DUI) of YazFlex for Endometriosis-associated Pelvic Pain and/or Dysmenorrhea
This study is a Japanese post-marketing surveillance (PMS) which is required by the regulatory authorities. General objective of PMS is to confirm the clinical usefulness, especially the safety profile of a drug under the routine…
- Trial name
- NCT03126747
- Testing
- BAY86-5300_YAZ-Flex
- Where
- Japan
- Volunteers
- 715 people
- Sponsor
- Bayer
Primary Dysmenorrhea
Diagnostic and Therapeutic Potential of Substance P/ NK1R Receptor in Primary Dysmenorrhea
Dysmenorrhea is characterized as excruciating menstrual cramps of uterine origin and is one of the most prevalent gynecological illnesses.
- Trial name
- NCT06317064
- Testing
- Ibuprofen and Aprepitant
- Where
- Pakistan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lahore Medical Research Center, LLP
Dysmenorrhea
Drotaverine in Dysmenorrhoea Treatment
The aim of the study is to show that the combination of drotaverine 80mg and ibuprofen 400 mg is more effective and as well-tolerated as ibuprofen 400 mg or drotaverine 80 mg administered alone, in the treatment of primary and…
- Trial name
- NCT00292747
- Testing
- Drotaverine, Ibuprofen
- Where
- Hungary
- Volunteers
- 480 people
- Sponsor
- Sanofi
Primary Dysmenorrhea
Effect of KYG0395 on Primary Dysmenorrhea
The purpose of this study is to further assess the efficacy, safety and dose-response of KYG0395 in the treatment of primary dysmenorrhea.
- Trial name
- NCT01588236
- Testing
- high dose KYG0395, lower dose KYG0395
- Where
- 23 sites in United States
- Volunteers
- 280 people
- Sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd
Endometriosis
A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain
This is a Phase 3, dose-escalation study designed to evaluate the safety and efficacy of both elagolix alone and elagolix plus estradiol/norethindrone acetate (E2/NETA) over 24 months in the management of endometriosis with…
- Trial name
- NCT03343067
- Testing
- elagolix, estradiol/norethindrone acetate (E2/NETA)
- Where
- 37 sites in United States
- Volunteers
- 11 people
- Sponsor
- AbbVie
Dysmenorrhea, Menstrual Cramps
A Single Group Study to Evaluate the Effects of a Topical Product on Cramps Associated With the Menstrual Cycle
This study evaluates the effectiveness of a topical product in reducing discomfort associated with menstrual cramps and back pain.
- Trial name
- NCT06939972
- Testing
- Topical Analgesic with Camphor and Menthol
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Rael
Endometriosis, Chronic Pelvic Pain
A Study of Women Receiving Standard of Care (SOC) for the Treatment of Pelvic Pain Due to Suspected or Confirmed Endometriosis and the Impact on the Disease or Symptom Progression.
This study will describe historic, current, and evolving treatment pathways, treatments, and interventions in women with a suspected or confirmed diagnosis of endometriosis in order to better understand the impact of early…
- Conditions
- Endometriosis, Chronic Pelvic Pain, Dysmenorrhea
- Trial name
- NCT04140175
- Where
- 117 sites in United States
- Volunteers
- 291 people
- Sponsor
- AbbVie
Menorrhagia, Dysmenorrhea
Prospective, Non-interventional, Multi-center Safety Study of Mirena for Heavy Menstrual Bleeding and Dysmenorrhea
The primary objective in this study is collecting post-marketing information on the safety. Thus, it includes information under the routine clinical practice on adverse events (AEs) and adverse drug reactions (ADRs) including…
- Trial name
- J-MIRAI (NCT02475356)
- Testing
- Levonorgestrel IUS (Mirena, BAY86-5028)
- Where
- Japan
- Volunteers
- 601 people
- Sponsor
- Bayer